Motor function, quality of life, and multidisciplinary treatment of patients with spinal muscular atrophy using disease-modifying therapies were evaluated. Assessments were performed according to the patient's functional capacity. Twenty patients were included in the study: 6 nonsitters and 14 sitters. Quality of life was assessed using the Pediatric Quality of Life Inventory 4.0 (PedsQL)—Neuromuscular Module. Low motor function performance and adequate quality of life were identified. Low motor function performance may be related to delayed onset of disease-modifying therapy; however, quality of life is good for a population receiving adequate treatment. Therefore, we conclude that the age at which drug treatment begins influences motor function scores and that adequate drug and multidisciplinary treatment improves the perception of quality of life.
FinkelRSMercuriEDarrasBT, et al.Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med.2017;377:1723–1732. doi:https://doi.org/10.1056/NEJMoa1702752
4.
MercuriEDarrasBTChiribogaCA, et al.Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med.2018;378:625–635. doi:https://doi.org/10.1056/NEJMoa1710504
5.
SchorlingDCPechmannAKirschnerJ. Advances in treatment of spinal muscular atrophy—new phenotypes, new challenges, new implications for care. J Neuromuscul Dis. 2020;7:1–13. doi:https://doi.org/10.3233/JND-190424
6.
QiaoYChiYGuJMaY. Safety and efficacy of nusinersen and risdiplam for spinal muscular atrophy: a systematic review and meta-analysis of randomized controlled trials. Brain Sci. 2023;13:1419. doi:https://doi.org/10.3390/brainsci13101419
7.
MercuriEFinkelRSMuntoniF, et al.Diagnosis and management of spinal muscular atrophy: Part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord.2018;28:103–115. doi:https://doi.org/10.1016/j.nmd.2017.11.005
8.
PierzchlewiczKKępaIPodogrodzkiJKotulskaK. Spinal muscular atrophy: the use of functional motor scales in the era of disease-modifying treatment. Child Neurol Open. 2021;8:2329048X2110087.
9.
StępieńAGajewskaERekowskiW. Motor function of children with sma1 and sma2 depends on the neck and trunk muscle strength, deformation of the spine, and the range of motion in the limb joints. Int J Environ Res Public Health. 2021;18. doi:https://doi.org/10.3390/ijerph18179134
10.
AlbrechtsenSSBornAPBoesenMS. Nusinersen treatment of spinal muscular atrophy—a systematic review. Dan Med J. 2020;67:1–12.
11.
MessinaSSframeliM. New treatments in spinal muscular atrophy: positive results and new challenges. J Clin Med. 2020;9:1–16. doi:https://doi.org/10.3390/jcm9072222
12.
VegaPGlisserCCastiglioniCVirginia AmézquitaMQuirolaMBarjaS. Quality of life in children and adolescents with spinal muscular atrophy. Rev Chil Pediatr. 2020;91:512–520.
Saúde MDA. Protocolo Clínico e Diretrizes Terapêuticas da Atrofia Muscular Espinhal 5q tipos 1 e 2. 2022.
15.
IannacconeSTHynanLSMortonABuchananRLimbersCAVarniJW. The PedsQL™ in pediatric patients with spinal muscular atrophy: feasibility, reliability, and validity of the Pediatric Quality of Life Inventory™ generic core scales and neuromuscular module. Neuromuscul Disord.2009;19:805–812. doi:https://doi.org/10.1016/j.nmd.2009.09.009
16.
GlanzmanAMMazzoneEMainM, et al.The Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability the CHOP INTEND is a reliable measure of motor skills in patients with SMA-I and neuromuscular disorders presenting in infancy. Neuromuscul Disord. 2010;20:155–161. doi:https://doi.org/10.1016/j.nmd.2009.11.014
17.
BishopKMMontesJFinkelRS. Motor milestone assessment of infants with spinal muscular atrophy using the Hammersmith Infant Neurological Exam – Part 2: experience from a nusinersen clinical study. Muscle Nerve. 2018;57:142–146. doi:https://doi.org/10.1002/mus.25705
BarlowJHerathNIBartram TorranceCBennettCWeiY. The Neonatal Behavioral Assessment Scale (NBAS) and Newborn Behavioral Observations (NBO) system for supporting caregivers and improving outcomes in caregivers and their infants. Cochrane Database Syst Rev.2018;2018. doi:https://doi.org/10.1002/14651858.CD011754.pub2
20.
Lizarazo MedinaJPOspina DíazJMManrique AbrilFG. Propiedades psicométricas de la escala NBAS aplicada a recién nacidos prematuros o con bajo peso. Revista Ciencias de la Salud. 2012;10:43–58.
Aragon-GawinskaKDaronAUliniciA, et al.Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen. Dev Med Child Neurol. 2020;62:310–314. doi:https://doi.org/10.1111/dmcn.14412
23.
CorattiGPeraMCLucibelloS, et al.Age and baseline values predict 12 and 24-month functional changes in type 2 SMA. Neuromuscul Disord.2020;30:756–764. doi:https://doi.org/10.1016/j.nmd.2020.07.005
24.
O’HagenJMGlanzmanAMMcDermottMP, et al.An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients. Neuromuscul Disord.2007;17:693–697. doi:https://doi.org/10.1016/j.nmd.2007.05.009
25.
MendonçaRHPolidoGJMatsuiC, et al.Real-world data from nusinersen treatment for patients with later-onset spinal muscular atrophy: a single center experience. J Neuromuscul Dis. 2020;8:101–108. doi:https://doi.org/10.3233/JND-200551
26.
ServaisLDayJWDe VivoDC, et al.Real-world outcomes in patients with spinal muscular atrophy treated with onasemnogene abeparvovec monotherapy: findings from the RESTORE registry. J Neuromuscul Dis. 2024;11:425–442. doi:https://doi.org/10.3233/JND-230122
27.
WirthBKarakayaMKyeMJMendoza-FerreiraN. Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what Comes next. Annu Rev Genomics Hum Genet. 2020;21:231–261. doi:https://doi.org/10.1146/annurev-genom-102319-103602
28.
CaluchoMBernalSAlíasL, et al.Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord.2018;28:208–215. doi:https://doi.org/10.1016/j.nmd.2018.01.003
29.
CaetanoRHauegenRCOsorio-De-CastroCGS. The incorporation of nusinersen by the Brazilian Unified National Health System: critical thoughts on the institutionalization of health technology assessment in Brazil. Cad Saude Publica. 2019;35:1–15.
30.
ChackoASlyPDWareRS, et al.Effect of nusinersen on respiratory function in paediatric spinal muscular atrophy types 1-3. Thorax. 2022;77:40–46. doi:https://doi.org/10.1136/thoraxjnl-2020-216564
31.
CarterGTHanJJAbreschRTJensenMP. The importance of assessing quality of life in patients with neuromuscular disorders. Am J Hosp Palliat Med.2007;23:493–497. doi:https://doi.org/10.1177/1049909106295278
32.
KocovaHDvorackovaOVondracekPHaberlovaJ. Health-related quality of life in children and adolescents with spinal muscular atrophy in the Czech Republic. Pediatr Neurol. 2014;50:591–594. doi:https://doi.org/10.1016/j.pediatrneurol.2014.01.037
YaoMMaYQianR, et al.Quality of life of children with spinal muscular atrophy and their caregivers from the perspective of caregivers: a Chinese cross-sectional study. Orphanet J Rare Dis. 2021;16:7. doi:https://doi.org/10.1186/s13023-020-01638-8
35.
McGrattanKEShellRDHurst-DavisR, et al.Patients with spinal muscular atrophy type 1 achieve and maintain bulbar function following onasemnogene abeparvovec Treatment1. J Neuromuscul Dis. 2023;10:531–540. doi:https://doi.org/10.3233/JND-221531
36.
Kant-SmitsKBartelsBvan der HeidenL, et al.The effect of disease-modifying therapies on lung function and respiratory muscle strength in spinal muscular atrophy: systematic review and meta-analysis. Respir Care. 2025;70:337–348. doi:https://doi.org/10.4187/respcare.12378
37.
PanagiotouPKanaka-GantenbeinCKaditisAG. Changes in ventilatory support requirements of spinal muscular atrophy (SMA) patients post gene-based therapies. Children. 2022;9:1207. doi:https://doi.org/10.3390/children9081207
38.
BarjaSMuñozCCancinoN, et al.Audiovisual stimulation in children with severely limited motor function: does it improve their quality of life?Rev Neurol. 2013;57:103–111.
39.
FinkelRSMercuriEMeyerOH, et al.Diagnosis and management of spinal muscular atrophy: Part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord.2018;28:197–207. doi:https://doi.org/10.1016/j.nmd.2017.11.004
40.
ZanoteliEAraujo AP deQCBeckerMM, et al.Consensus from the Brazilian Academy of Neurology for the diagnosis, genetic counseling, and use of disease-modifying therapies in 5q spinal muscular atrophy. Arq Neuropsiquiatr. 2024;82:001–018.
41.
AldukainMAldukainAHobaniA, et al.The impact of nusinersen treatment on respiratory function in patients with spinal muscular atrophy. A systematic review. J Clin Med. 2024;13:6306.
42.
González-MeladoF. El mejor interés del niño con SMA I. Reflexiones sobre los tratamientos de soporte vital en niños con atrofia muscular espinal tipo I. 2014.
